Fountain Therapeutics: an AI-based platform to reverse cellular aging

Fountain’s AI-driven platform measures cellular age as the basis for anti-aging drug screens

Fountain is using an unbiased data-driven approach to identify compounds that reverse the biological process of aging, and in contrast to the traditional disease hypothesis-driven approach, the company is agnostic to indication.

“Eighty percent of the healthcare world is in our purview as an aging-related disease company,” CEO John Dimos told BioCentury. “The way we are looking to discover and develop drugs might be changing

Read the full 654 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers